Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03519230 | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | PHASE3 | ACTIVE NOT_RECRUITING | 224 | — | — | May 14, 2018 | Jan 30, 2027 | Mar 16, 2026 | 28 | China |
| Arm | Type | Description |
|---|---|---|
| Treatment arm | EXPERIMENTAL | - |
| Placebo arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Pamiparib capsule | DRUG | 60 mg twice daily (BID), orally (per os-PO) |
| Placebo capsule | DRUG | 60mg BID, PO |
Key Inclusion Criteria: 1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer) 2. Completion of ≥2 previous platinum-containing regimens (eg, carboplatin or cisplatin) 3. Complete response (CR) or partial response (PR) a...